Proficio Capital Partners LLC bought a new position in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD - Free Report) in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor bought 14,827 shares of the biopharmaceutical company's stock, valued at approximately $272,000.
Several other institutional investors have also recently made changes to their positions in ACAD. R Squared Ltd bought a new position in ACADIA Pharmaceuticals during the 4th quarter valued at approximately $47,000. Quest Partners LLC increased its position in ACADIA Pharmaceuticals by 42.3% during the 3rd quarter. Quest Partners LLC now owns 3,520 shares of the biopharmaceutical company's stock valued at $54,000 after buying an additional 1,047 shares in the last quarter. KBC Group NV increased its position in ACADIA Pharmaceuticals by 67.0% during the 4th quarter. KBC Group NV now owns 5,093 shares of the biopharmaceutical company's stock valued at $93,000 after buying an additional 2,044 shares in the last quarter. PDT Partners LLC bought a new position in ACADIA Pharmaceuticals during the 3rd quarter valued at approximately $203,000. Finally, Landscape Capital Management L.L.C. bought a new position in ACADIA Pharmaceuticals during the 3rd quarter valued at approximately $255,000. Institutional investors own 96.71% of the company's stock.
Analyst Upgrades and Downgrades
Several analysts have commented on ACAD shares. Cantor Fitzgerald reiterated an "overweight" rating and set a $28.00 target price on shares of ACADIA Pharmaceuticals in a research note on Thursday, February 27th. Needham & Company LLC reiterated a "buy" rating and set a $28.00 target price on shares of ACADIA Pharmaceuticals in a research note on Thursday, February 27th. Guggenheim downgraded ACADIA Pharmaceuticals from a "buy" rating to a "neutral" rating and cut their target price for the company from $23.00 to $20.00 in a research note on Friday, January 3rd. StockNews.com upgraded ACADIA Pharmaceuticals from a "hold" rating to a "buy" rating in a research note on Saturday. Finally, HC Wainwright restated a "buy" rating and issued a $27.00 price target on shares of ACADIA Pharmaceuticals in a research note on Thursday, February 27th. Eight analysts have rated the stock with a hold rating and ten have given a buy rating to the stock. According to MarketBeat.com, the company currently has an average rating of "Moderate Buy" and a consensus target price of $24.00.
View Our Latest Analysis on ACAD
Insider Transactions at ACADIA Pharmaceuticals
In related news, Director Elizabeth A. Garofalo sold 4,919 shares of ACADIA Pharmaceuticals stock in a transaction dated Wednesday, March 5th. The stock was sold at an average price of $18.23, for a total value of $89,673.37. Following the completion of the transaction, the director now owns 17,595 shares in the company, valued at approximately $320,756.85. This trade represents a 21.85 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Over the last three months, insiders have sold 6,167 shares of company stock valued at $114,583. 28.30% of the stock is currently owned by insiders.
ACADIA Pharmaceuticals Stock Performance
Shares of ACAD stock opened at $17.19 on Wednesday. ACADIA Pharmaceuticals Inc. has a 12-month low of $14.15 and a 12-month high of $20.68. The stock's 50-day moving average price is $18.51 and its 200-day moving average price is $16.95. The stock has a market capitalization of $2.87 billion, a price-to-earnings ratio of 22.04 and a beta of 0.43.
About ACADIA Pharmaceuticals
(
Free Report)
ACADIA Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider ACADIA Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and ACADIA Pharmaceuticals wasn't on the list.
While ACADIA Pharmaceuticals currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
